|
Indications and Dosage
Oral
Immunosuppressant in renal transplant patients Adult: 1-3 mg/kg daily. Higher doses (>5 mg/kg daily) have been used. Oral Nephrotic syndrome, Rheumatoid arthritis Adult: For nephrotic syndrome associated with primary glomerular disease or lupus nephritis: 50 mg tid.
|
|
Contraindications
Hypersensitivity.
|
|
Special Precautions
Doses must be reviewed regularly in renal transplant patients to ensure that plasma drug level is in the therapeutic range. Monitor serum uric acid regularly during treatment. Increased risk of infections and malignancy. Use with caution in patients with active disorders of the GI tract. Live vaccines should also be avoided.
|
|
Adverse Reactions
Hyperuricaemia. GI symptoms.
|
|
Drug Interactions
Increased risk of rhabdomyolysis when used concurrently with bezafibrate.
|
|
Action
Description:
Mechanism of Action: Mizoribine is an imidazole nucleoside originally isolated from Eupenicillium brefedianum. It is an immunosuppressant that works by blocking the purine biosynthesis pathway and inhibiting mitogen-stimulated T-and B-cell proliferation. Pharmacokinetics: Absorption: Rapidly absorbed from the intestines. Excretion: Almost completely excreted within 24 hr; mainly in urine (85%) and in the bile (1%). |
|
MIMS Class
|
Sign Out
